Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $178 | $60 | $27 | $6 |
| % Growth | 195.3% | 122% | 341.5% | – |
| Cost of Goods Sold | $0 | $10 | $128 | $111 |
| Gross Profit | $178 | $50 | -$101 | -$105 |
| % Margin | 100% | 83.6% | -370.5% | -1,706.6% |
| R&D Expenses | $149 | $127 | $128 | $111 |
| G&A Expenses | $81 | $72 | $63 | $57 |
| SG&A Expenses | $81 | $72 | $63 | $57 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $16 | $0 | -$1 | $4 |
| Operating Expenses | $247 | $188 | $191 | $168 |
| Operating Income | -$69 | -$138 | -$164 | -$162 |
| % Margin | -38.6% | -229% | -604% | -2,638.6% |
| Other Income/Exp. Net | $1 | $26 | -$1 | $5 |
| Pre-Tax Income | -$67 | -$113 | -$163 | -$157 |
| Tax Expense | $4 | $1 | $2 | $1 |
| Net Income | -$71 | -$114 | -$165 | -$158 |
| % Margin | -39.8% | -188.9% | -609.5% | -2,571% |
| EPS | -0.28 | -0.57 | -1.02 | -1.02 |
| % Growth | 50.9% | 44.1% | 0% | – |
| EPS Diluted | -0.28 | -0.57 | -1.02 | -1.02 |
| Weighted Avg Shares Out | 252 | 201 | 161 | 156 |
| Weighted Avg Shares Out Dil | 252 | 201 | 161 | 156 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $6 | $2 | $1 |
| Interest Expense | $3 | $0 | $0 | $0 |
| Depreciation & Amortization | $11 | $10 | $6 | $7 |
| EBITDA | -$53 | -$128 | -$156 | -$156 |
| % Margin | -29.6% | -212.7% | -573.1% | -2,531.8% |